Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $635.11M. The enterprise value is $72.30M.
Market Cap$635.11M
Enterprise Value$72.30M
Share Statistics
Bicara Therapeutics Inc. has 54,562,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,562,840
Owned by Insiders37.30%
Owned by Institutions0.28%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -16.75%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-16.75%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicara Therapeutics Inc. is ―. Bicara Therapeutics Inc.’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.93
Price to FCF―
Price to Operating Cash Flow-6.12
PEG Ratio―
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0.00 and earned -68.00M in profits. Earnings per share was -1.25.
Revenue0.00
Gross Profit-56.00K
Operating Income-82.39M
Pretax Income-67.81M
Net Income-68.00M
EBITDA-67.75M
Earnings Per Share (EPS)-1.25
Cash Flow
In the last 12 months, operating cash flow was -100.96M and capital expenditures -48.00K, giving a free cash flow of -101.00M billion.
Operating Cash Flow-100.96M
Free Cash Flow-101.00M
Free Cash Flow per Share-1.85
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.73
52-Week Price Change-54.86%
50-Day Moving Average10.52
200-Day Moving Average13.95
Relative Strength Index (RSI)56.13
Average Volume (3m)322.75K
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is Nov 18, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 27.93, with Debt / Equity ratio of 0.51%
Current Ratio27.93
Quick Ratio27.93
Debt to Market Cap<0.01
Net Debt to EBITDA7.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid 187.00K in taxes.
Income Tax187.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -6.78, with an EV/FCF ratio of -6.14.
EV to Sales0.00
EV to EBITDA-6.78
EV to Free Cash Flow-6.14
EV to Operating Cash Flow-6.14
Balance Sheet
Bicara Therapeutics Inc. has $436.61M in cash and marketable securities with $2.24M in debt, giving a net cash position of -$434.37M billion.
Cash & Marketable Securities$436.61M
Total Debt$2.24M
Net Cash-$434.37M
Net Cash Per Share-$7.96
Tangible Book Value Per Share$9.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $33.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.17
Price Target Upside184.97% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―